Juvenile Hemochromatosis

Clinical characteristics.

Juvenile hemochromatosis is characterized by onset of severe iron overload occurring typically in the first to third decades of life. Males and females are equally affected. Prominent clinical features include hypogonadotropic hypogonadism, cardiomyopathy, glucose intolerance and diabetes, arthropathy, and liver fibrosis or cirrhosis. Hepatocellular cancer has been reported occasionally. The main cause of death is cardiac disease. If juvenile hemochromatosis is detected early enough and if blood is removed regularly through the process of phlebotomy to achieve iron depletion, morbidity and mortality are greatly reduced.

Diagnosis/testing.

The diagnosis of juvenile hemochromatosis is established in a proband with clinical and laboratory features of iron overload by identification of biallelic pathogenic variants in HAMP or HJV on molecular genetic testing. Individuals with suggestive features of juvenile hemochromatosis who do not have biallelic HAMP or HJV pathogenic variants identified on molecular genetic testing should have further evaluation by imaging and/or liver biopsy.

Management.

Treatment of manifestations: Phlebotomy for treatment of iron overload as for HFE hemochromatosis: phlebotomy of 1 unit of blood (~200 mg of iron) 1x/week for up to 2-3 years to reduce iron stores to desired levels (serum ferritin concentration ~50 ng/mL), followed by phlebotomies to maintain normal serum iron levels. Conventional treatment of secondary complications including hypogonadotropic hypogonadism, arthropathy, cardiac failure, liver disease, and diabetes mellitus as indicated. Hypogonadism is treated with testosterone replacement in males and cyclical estrogen and progesterone therapy in fertile females. Arthropathy is treated with analgesics and NSAIDs. Cardiac failure and arrhythmias require treatment as per cardiologist. Glucose intolerance or diabetes may require oral agents or insulin administration.

Prevention of primary manifestations: Individuals with biochemical evidence of iron overload but without evidence of organ dysfunction or failure should be encouraged to undergo regular phlebotomies until excess iron stores are depleted to prevent the development of complications associated with excess iron stores.

Prevention of secondary complications: Hormone replacement therapy may prevent osteoporosis.

Surveillance: Monitor those at risk with annual measurement of serum ferritin concentration and transferrin saturation starting in early childhood. For individuals with iron overload: serum ferritin every 4-8 phlebotomies during the induction phase; every 1-2 phlebotomies as ferritin levels approach the target of 50 ng/mL; liver function tests and fibroelastography every 6-24 months according to severity of liver dysfunction; abdominal ultrasound and serum alpha-fetoprotein concentration every 6 months in those with severe fibrosis or cirrhosis to monitor for hepatocellular cancer; cardiac ultrasound and MR-based quantitation of iron according to the severity of cardiac dysfunction; Holter EKG as needed to evaluate for arrhythmias; serum FSH, LH, and testosterone or estradiol every 12 months or as needed; fasting and postprandial serum glucose and Hgb A1c every 6-12 months according to needs; vitamin D, PTH, serum and urinary calcium and phosphorus, C-terminal telopeptide every 12 months according to needs; DXA every 24 months or as needed.

Agents/circumstances to avoid: Alcohol consumption; ingestion of iron-containing preparations and supplemental vitamin C; handling or eating uncooked shellfish or marine fish because of risk of fatal septicemia from the marine bacterium V vulnificus.

Evaluation of relatives at risk: It is appropriate to clarify the clinical/genetic status of all at-risk family members (i.e., sibs) of an affected individual in order to identify as early as possible those who would benefit from early monitoring for the development of iron overload. If juvenile hemochromatosis is detected before evidence of organ damage, treatment via phlebotomy can reverse or prevent many of the secondary complications resulting from organ damage. Evaluation can include serum iron indices (i.e., serum iron, transferrin saturation, and serum ferritin), serum transaminases, C-reactive protein, and molecular genetic testing in relatives at risk before evidence of organ damage from iron overload.

Genetic counseling.

Juvenile hemochromatosis is inherited in an autosomal recessive manner. If each parent is known to be heterozygous for a HAMP or HJV pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an unaffected carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and prenatal testing are possible if both pathogenic variants in the family have been identified.

Suggestive Findings

Juvenile hemochromatosis should be suspected in individuals with the following findings:

• Less specific symptoms in the first decade (e.g., fatigue, arthralgia, lack of appetite), which are often erroneously attributed to iron deficiency anemia
• Decreased libido, impotence (males), and amenorrhea (females) in adolescents and/or young adults suggesting hypogonadotropic hypogonadism
• Hepatomegaly, slight alterations of serum transaminases suggesting liver disease or severe fibrosis/cirrhosis
• Fasting hyperglycemia, glucose intolerance, or frank diabetes
• Arrhythmias, dyspnea on exertion, heart failure suggesting cardiomyopathy
• Arthropathy and osteoporosis
• Hyperpigmentation

Note: Many of these features are evident before age 30 years, although they may appear at a later age in some individuals [Kong et al 2019].

Laboratory features

• Transferrin saturation, which is typically high, often reaching 100% (normal values 16%-45%). Normal transferrin saturation excludes the diagnosis of juvenile hemochromatosis.
• Serum ferritin concentration, which is increased relative to the normal values for age and sex according to data published by the World Health Organization:
  • Upper normal value in male and female children and young adolescents: 100-125 ng/mL
  • Upper normal value in premenopausal adult women: 150 ng/mL, and in postmenopausal women: 250 ng/mL [Milman et al 2003]
  • Upper normal value in healthy adult men: 400 ng/mL [Milman et al 2002]
  • In the earlier stages of juvenile hemochromatosis, serum ferritin can be slightly increased, but can rapidly increase over 1000 ng/mL and even much higher.

Establishing the Diagnosis

The diagnosis of juvenile hemochromatosis is established in a proband by identification of biallelic pathogenic variants in HAMP or HJV on molecular genetic testing (see Table 1) [Piperno 2013, Porto et al 2016, Brissot et al 2018].

Molecular genetic testing approaches can include use of a multigene panel or single-gene testing:

• An iron overload multigene panel that includes HAMP, HJV, HFE, and other genes of interest (see Differential Diagnosis) is most likely to identify the genetic cause of the condition, including digenic forms of hemochromatosis and genetic variants in modifier genes [Badar et al 2016, Faria et al 2016, Wallace & Subramaniam 2016]. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this GeneReview. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests. For this disorder a multigene panel that also includes deletion/duplication analysis is recommended (see Table 1).
  For an introduction to multigene panels click here. More detailed information for clinicians ordering genetic tests can be found here.
• Single-gene testing can be considered in individuals with early-onset iron overload. Sequence analysis of HJV can be performed first to detect small indels and missense, nonsense, and splice site variants. If no or only one pathogenic variant is found, perform sequence analysis of HAMP. If no or only one pathogenic variant is identified, consider other genes of interest (see Differential Diagnosis). If no or only one pathogenic variant is identified, perform gene-targeted deletion/duplication analysis of HAMP, HJV, and other genes of interest (see Differential Diagnosis) to detect intragenic deletions or duplications.

Clinical Description

To date, approximately 120 individuals have been identified with juvenile hemochromatosis [De Gobbi et al 2002, Merryweather-Clarke et al 2003, Roetto et al 2003, Delatycki et al 2004, Jacolot et al 2004, Matthes et al 2004, Roetto et al 2004, Island et al 2009, Lok et al 2009, Hattori et al 2012, Kong et al 2019]. The following description of the phenotypic features associated with this condition is based on these reports.

Juvenile hemochromatosis is characterized by early-onset severe iron overload. Individuals with juvenile hemochromatosis typically present in the first to third decade of life; however, adult presentation has been described in individuals with HJV hemochromatosis [Koyama et al 2005, Ravasi et al 2018, Kong et al 2019], expanding the spectrum of disease phenotypes related to HJV pathogenic variants from classic juvenile hemochromatosis at one extreme to a late-onset adult form at the other extreme. Males and females are equally affected.

Individuals with juvenile hemochromatosis are rarely diagnosed before significant iron overload occurs. Prominent clinical features include hypogonadotropic hypogonadism, cardiomyopathy, diabetes and glucose intolerance, arthropathy, and liver fibrosis or cirrhosis.

Cardiac. The prevalence of cardiac disease is strikingly high [De Gobbi et al 2002, Kong et al 2019] and in some individuals is the presenting finding [Filali et al 2004]. Myocardial iron accumulation induces the development of restrictive cardiomyopathy with early diastolic dysfunction that may progress towards dilated cardiomyopathy. Heart failure is the main cause of death in untreated individuals with juvenile hemochromatosis [Murphy & Oudit 2010]. A variety of arrhythmias and sudden death can also occur in individuals with severe iron overload although further investigations to clarify the etiology and clinical relevance of iron overload-induced arrhythmias are needed [Shizukuda & Rosing 2019]. Iron removal can significantly improve and/or normalize cardiac function [Murphy & Oudit 2010].

Hypogonadotropic hypogonadism characterized by low levels of gonadotropins (FSH and LH) and testosterone is the most frequent endocrinologic complication in individuals with iron overload due to juvenile hemochromatosis [De Gobbi et al 2002, Borgna-Pignatti et al 2004]. It causes decreased libido and infertility, amenorrhea in females, and impotence in males, and contributes to the development of osteoporosis. Iron removal in early stages can lead to symptomatic improvement or resolution and normalization of hormonal indices [Angelopoulos et al 2006, Pelusi et al 2016].

Diabetes mellitus. Most of the information on diabetes development has been obtained in individuals with HFE hemochromatosis, where the pathogenesis of glucose intolerance and diabetes is likely multifactorial. Autopsy findings in individuals with hemochromatosis showed variable iron deposition in the exocrine pancreas and in beta cells together with loss of endocrine granules. It can be hypothesized that a severe and rapid iron overload in the exocrine pancreas could induce an initial beta-cell oxidative stress followed by iron accumulation and decreased insulin secretory capacity secondary to beta-cell apoptosis and desensitization of glucose-induced insulin secretion [Backe et al 2016]. Glucose intolerance or diabetes may require oral agents or insulin administration. Phlebotomy has a variable impact on diabetes control. In general, it may prevent progression if started in the earlier stages of disease, although the majority of individuals with diabetes will experience no significant change or worsening in their glucose metabolism control [Angelopoulos et al 2007, Pelusi et al 2016].

Liver. Although hepatomegaly is usually included among the earlier manifestations of juvenile hemochromatosis there is no information on its frequency as it is often poorly noted in clinical evaluations. Because the liver can compensate for iron toxicity, cirrhosis takes decades to develop. While in individuals with HFE hemochromatosis a serum ferritin value above 1000 ng/mL is a validated marker of increased risk of severe hepatic fibrosis/cirrhosis [Allen et al 2010], there are no data available for juvenile hemochromatosis. Therefore, assessment by liver fibroelastography and/or liver biopsy is mandatory. Environmental (e.g., alcohol consumption, steatosis, coexistent viral infection) and possibly genetic factors can modify the risk for cirrhosis [Brissot et al 2018]. Based on data related to other liver disease and HFE hemochromatosis [Falize et al 2006] it can be assumed that iron depletion can improve fibrosis unless cirrhosis is fully established. Hepatocellular carcinoma is rarely reported in individuals with juvenile hemochromatosis [Ramzan et al 2017]. A possible explanation is that untreated individuals with juvenile hemochromatosis die prematurely as a result of cardiac complications.

Skeletal. Articular symptoms, arthralgias, and/or arthritis was reported in seven of eight individuals with HJV hemochromatosis [Vaiopoulos et al 2003]. The age at onset of arthropathy ranged from 20 to 45 years. In two individuals arthropathy preceded other symptoms of juvenile hemochromatosis. The involved joints were most frequently metacarpophalangeal joints; knees, lumbar spine, and shoulder and metatarsophalangeal joints were variably involved. Four of the six individuals evaluated had osteopenia or osteoporosis, common complications in individuals with prolonged hypogonadism. However, a more recent study of 73 individuals with HJV hemochromatosis reported a very low frequency of osteopathy (7%) [Kong et al 2019] – a finding to be taken with caution because osteopenia and osteoporosis can be underestimated if not sought with appropriate investigations through bone densitometry (DXA, dual-energy x-ray absorptiometry). Iron removal, in contrast with the visceral manifestations, often did not mitigate orthopedic complications [Sahinbegovic et al 2010].

Skin. A recent review reported hyperpigmentation in approximately 25% of individuals with HJV hemochromatosis [Kong et al 2019] – a finding that contrasts with older reports of skin hyperpigmentation at diagnosis in about 90% of individuals with hemochromatosis. Hyperpigmentation developed very gradually. This may suggest that iron-induced skin changes take too long to manifest in the majority of individuals with juvenile hemochromatosis.

If juvenile hemochromatosis is detected early and treated with phlebotomy to achieve iron depletion, morbidity and mortality are greatly reduced.

Other. Although individuals with juvenile hemochromatosis may develop adrenocortical insufficiency or hypothyroidism, these complications are rare [Varkonyi et al 2000, Pelusi et al 2016].

Heterozygotes and digenic inheritance. Heterozygous pathogenic variants in HAMP, HJV, and/or TFR2 have been shown to increase the risk for iron overload in HFE p.Cys282Tyr heterozygotes [Merryweather-Clarke et al 2003] and to increase iron burden in HFE p.Cys282Tyr homozygotes [Jacolot et al 2004, Majore et al 2004, Pietrangelo et al 2005]. However, only a very small proportion of individuals with HFE hemochromatosis are reported to have polygenic inheritance due to pathogenic variants in HAMP and HJV.

Genotype-Phenotype Correlations

No genotype-phenotype correlations can be provided for HAMP juvenile hemochromatosis due to the small number of reported individuals.

HJV. More than 90% of homozygotes with HJV pathogenic variants in exons 2 and/or 3 developed hemochromatosis before age 30, compared with only 66% of homozygotes with HJV pathogenic variants in exon 4 [Kong et al 2019], indicating that the genetic defects in exons 2 and 3 may have a more deleterious effect on HJV function.

Nomenclature

Despite use of the locus names HFE2A and HFE2B for the two juvenile hemochromatosis genes (HJV and HAMP, respectively), juvenile hemochromatosis is not associated with pathogenic variants in HFE – mutation of which causes HFE hemochromatosis, an adult-onset disorder of iron storage.

Prevalence

Juvenile hemochromatosis is rare; global HJV pathogenic allele frequency has been estimated at 0.000316-0.00074 [Wallace & Subramaniam 2016]. Affected individuals have been reported worldwide. The variant p.Gly320Val is the most prevalent pathogenic variant (>50%) reported to date; p.Cys321Ter is the most frequent pathogenic variant in individuals of Chinese ancestry; p.Gln312Ter (also reported in individuals of Chinese ancestry) and p.Asp249His are the predominant pathogenic variants in Japan [Ikuta et al 2017]; p.Arg385Ter recurs in North Africa and Italy [Lanzara et al 2004, Kong et al 2019]. The variant p.Ala310Gly is common in African Americans and Brazilians, but its role is still undefined [Lee et al 2004, Santos et al 2011]. Table 7 reports the most frequent pathogenic variants according to ethnicity.

Primary Iron Overload Disorders

Secondary Iron Overload Disorders

Transfusional iron overload. One unit of packed red blood cells contains approximately 200–250 mg of iron. Individuals requiring frequent transfusions due to inherited anemias (e.g., thalassemia major, Diamond-Blackfan anemia) will develop severe iron overload and iron-related complications at an early age if untreated. Other transfusion-dependent iron overload conditions include survivors of bone marrow transplant, myelodysplastic disorders, myeloproliferative syndromes, and aplastic anemia. Iron accumulation occurs initially in the reticuloendothelial macrophages. After iron excess overwhelms homeostatic mechanisms in macrophages, transferrin becomes fully saturated leading to elevated non-transferrin-bound iron and parenchymal iron overload [Porter et al 2014].

Iron loading anemias. This group of disorders includes: non-transfusion-dependent thalassemia (thalassemia intermedia), congenital and acquired sideroblastic anemias, congenital dyserythropoietic anemias, pyruvate kinase deficiency, and other anemias, all characterized by ineffective erythropoiesis. Chronic anemia, hypoxia, and ineffective erythropoiesis activate erythroid signaling, suppressing liver hepcidin synthesis and leading to increased intestinal iron absorption and iron release from macrophages [Muckenthaler et al 2017]. High transferrin saturation and ferritin, and parenchymal iron overload are typical manifestations of this group of disorders.

African iron overload (OMIM 601195) occurs in individuals with a predisposition to iron overload that is exacerbated by excessive intake of dietary iron. Iron accumulation primarily involves reticuloendothelial macrophages and later hepatocytes. It is particularly prevalent among Africans who drink a traditional beer brewed in non-galvanized steel drums. However, serious iron overload does not develop in all beer drinkers, and not all individuals with iron overload consume excessive amounts of the beer, suggesting that other yet-to-be defined iron-related genes predispose to the condition. SCL40A1 pathogenic variant p.Gln284His appeared to be unique to African populations and associated with a mild iron-loading tendency [Gordeuk et al 2003]. However, a subsequent study failed to show that p.Gln284His was responsible for iron overload, while it could influence the inflammatory response in African populations [McNamara et al 2005].

Neonatal hemochromatosis (NH) is a severe liver disorder associated with extrahepatic siderosis with the same distribution seen in juvenile hemochromatosis (sparing the reticulo-endothelial system). NH is characterized by high mortality. Recurrence is approximately 80% in the offspring of affected women. Because it was observed in sibs, NH was classified as a familial hemochromatosis (OMIM 231100). However, clinical evidence now suggests that NH is the consequence of fetal liver injury due to a variety of causes. Most NH is ascribed to gestational alloimmune liver disease (GALD; NH-GALD). GALD can also produce liver disease without extrahepatic siderosis and the absence of siderosis in the newborn liver does not exclude the diagnosis of GALD.

Evaluations Following Initial Diagnosis

To establish the extent of disease in an individual diagnosed with juvenile hemochromatosis, the evaluations summarized Table 4 (if not performed as part of the evaluation that led to the diagnosis) are recommended.

Treatment of Manifestations

Management and treatment recommendations for juvenile hemochromatosis stated here are based on the established HFE-associated hemochromatosis recommendations when specific juvenile hemochromatosis information may not exist.

Treatment of iron overload. Phlebotomy is the therapy of choice in juvenile hemochromatosis and follows the same principles as the treatment of HFE hemochromatosis. It is simple, safe, and effective. Affected individuals should be encouraged to follow a regimen of phlebotomy of one unit of blood once weekly [Adams & Barton 2010]. Approximately 200 mg of iron are removed per unit of blood depending on the individual's hematocrit. Because individuals with juvenile hemochromatosis are usually severely iron overloaded, phlebotomy therapy may take more than one year and may require combined treatment with iron chelating agents in some individuals with very severe iron overload. See Iron chelators (following).

Hemoglobin should be monitored prior to phlebotomy; if the value is less than 11 g/dL, the treatment schedule is modified to every other week [Adams & Barton 2010, Brissot et al 2018]. Systematic administration of erythropoietin has been successful in maintaining the hematocrit in individuals who failed to mount an adequate bone marrow response to the phlebotomy regimen [De Gobbi et al 2000].

Serum ferritin concentration reflects body iron stores and is used to monitor the progress of therapy; it is expected to fall progressively, along with iron mobilization. Measuring serum ferritin concentration every 4-8 phlebotomies according to the amount of iron overload is reasonable; however, once serum ferritin concentration is below 100 ng/mL, it should be measured more often.

Individuals are treated until the serum ferritin is approximately 50 ng/mL, a value in the lower reference range that signifies that there is little or no storage iron [Adams & Barton 2010]. Experimental studies demonstrated that nonheme iron absorption is markedly increased and hepcidin is markedly decreased by phlebotomy inducing very low serum ferritin. This could lead to unnecessary induction and maintenance phlebotomy [Lynch et al 1989, Piperno et al 2007].

Transferrin saturation usually decreases much less rapidly in response to phlebotomy therapy than the serum ferritin level. It may remain increased when body iron stores and serum ferritin values have already reached target levels. Despite successful iron depletion, transferrin saturation often remains increased in individuals with juvenile hemochromatosis, and reducing transferrin saturation to low-normal values may result in iron deficiency. Thus, experts recommend that serum ferritin, not transferrin saturation, be used as the indicator for cessation of phlebotomy induction therapy [Adams & Barton 2010, Brissot et al 2018].

Erythrocytoapheresis can be a rapid and safe alternative treatment, but it requires special apparatus and facilities and has limited availability. Although this treatment is excellent in selected individuals, erythropoietin stimulation may be required to maintain adequate hemoglobin level. This treatment may be preferred for individuals with severe iron overload and individuals whose clinical condition requires maintaining the isovolemic status or sparing of plasma proteins as in severe cardiomyopathy or advanced liver disease [Rombout-Sestrienkova et al 2016, Brissot et al 2018].

Iron chelators can be used when phlebotomies are contraindicated or in combined therapy in individuals with severe iron overload. There are few reports using iron chelators in individuals with hemochromatosis. Deferoxamine therapy is cumbersome, requiring daily parenteral administration (subcutaneous infusions), and can lead to poor compliance over the long term [Adams & Barton 2010]. Deferasirox is an oral iron chelator whose efficiency has been reported in individuals with juvenile hemochromatosis [Maeda et al 2011, Masera et al 2013]. It can be used as an off-label therapy in individuals with hemochromatosis.

Maintenance therapy. The frequency of phlebotomies is adjusted to maintain normal serum ferritin concentration and transferrin saturation. When iron removal is not urgent, phlebotomies could be spaced further apart according to the responsiveness of the bone marrow to restore adequate hematocrit. Usually four to six phlebotomies annually are sufficient. The individual should permanently continue on this schedule of phlebotomy maintenance therapy.

Treatment of complications. Treatment does not essentially differ from the conventional treatment applied in other situations:

• Hypogonadism is treated with testosterone replacement in males and cyclical estrogen and progesterone therapy in fertile females. Although iron-induced pituitary hypogonadism is generally considered irreversible, it has been shown that gonadotropin cell dysfunction can be reversed when specific treatment is introduced early in the progression of the disease [Angelopoulos et al 2006, Pelusi et al 2016]. Therefore, hormonal substitution treatment should be withdrawn to reassess gonadotropin secretion when body iron stores have been normalized.
• Limited data regarding treatment of the joint involvement of hemochromatosis exist. Treatment relies on symptomatic measures with the use of analgesics and NSAIDs. Colchicine can be useful during flares most probably due to calcium pyrophosphate deposition. Intra-articular corticosteroid injections can be used but no relevant published data is available. Some data suggest the possible efficacy of phlebotomy but its effects, if any, are unpredictable. Joint prosthetic replacement (mainly hip and knee) is an option [Guggenbuhl et al 2011].
• Cardiac failure and arrhythmias require treatment as per cardiologist. Iron removal is mandatory because of the evidence of its significant effect in improving cardiac function [Murphy & Oudit 2010]. If left untreated, cardiac disease progresses rapidly and becomes refractory to treatment, leading to death in most affected individuals. Orthotopic heart transplantation has been used on occasion [Caines et al 2005].
• Based on data related to other liver disease and HFE hemochromatosis [Falize et al 2006] it can be assumed that iron depletion can improve fibrosis unless cirrhosis is fully established. Nevertheless, individuals with liver cirrhosis require endoscopic evaluation to document the presence of varices and ultrasounds every six months to monitor (nodular evolution, portal hypertension, gallstones). In general, hemochromatosis remains an uncommon indication for liver transplantation usually limited to individuals with hemochromatosis and hepatocellular carcinoma. Pretransplant iron depletion is recommended if tolerated as it reduces the risk of cardiac and infectious complications postoperatively [Dar et al 2009, Brissot et al 2018].
• Glucose intolerance or diabetes may require oral agents or insulin administration. Phlebotomy has a variable impact on diabetes control. In general, it may prevent progression if started in the earlier stages of disease, although the majority of individuals with diabetes will experience no significant change or worsening in their glucose metabolism control [Angelopoulos et al 2007, Pelusi et al 2016].

Prevention of Primary Manifestations

Individuals with biochemical evidence of iron overload but without evidence of organ dysfunction or failure should be encouraged to undergo regular phlebotomies until excess iron stores are depleted to prevent the development of complications associated with excess iron stores.

Treatment by phlebotomy in presymptomatic stages can prevent organ damage.

Prevention of Secondary Complications

Hormone replacement therapy may prevent the development of osteoporosis.

Surveillance

If hepatic cirrhosis is identified, monitoring for hepatocellular cancer (HCC) is recommended. The imaging test most widely used for surveillance is ultrasonography (US), and a 6-month interval represents a reasonable choice. The performance of US in early detection of HCC is highly dependent on the expertise of the operator and the quality of the equipment. Thus, special training for ultrasonographers is recommended. AFP is the most widely tested biomarker in HCC, but it has a suboptimal performance as a serologic test for surveillance [European Association for the Study of the Liver-European Organisation for Research and Treatment of Cancer 2012].

Agents/Circumstances to Avoid

Avoid the following [Adams & Barton 2010, Brissot et al 2018]:

• Alcohol consumption, which has a synergistic effect with iron-induced liver damage in individuals with liver damage
• Iron-containing preparations and supplemental vitamin C
• Handling or eating uncooked shellfish or marine fish, because of susceptibility to fatal septicemia from the marine bacterium V vulnificus

Evaluation of Relatives at Risk

Once a diagnosis of juvenile hemochromatosis has been made in a family, it is appropriate to clarify the clinical/genetic status of all at-risk family members (i.e., sibs) of an affected individual in order to identify as early as possible those who would benefit from early monitoring for the development of iron overload. If juvenile hemochromatosis is detected before evidence of organ damage, treatment via phlebotomy can reverse or prevent many of the secondary complications resulting from organ damage.

Evaluation of at-risk family members can include:

• Serum iron indices (serum iron, transferrin saturation, and serum ferritin) and serum transaminases as first evaluation of coexistent liver damage and C-reactive protein to exclude inflammatory conditions that can influence serum iron indices;
• Molecular genetic testing (if the HAMP or HJV pathogenic variants have been identified in an affected family member).

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

Pregnancy Management

All pregnant women with juvenile hemochromatosis should be under the care of a maternal-fetal medicine specialist, an endocrinologist, and a cardiologist. Preferably women with juvenile hemochromatosis should be seen by these specialists prior to becoming pregnant.

Pregnancy in women with untreated juvenile hemochromatosis is high risk because the increased hemodynamic burden of pregnancy can precipitate cardiac failure in women with an underlying cardiomyopathy. Of note, it is critically important for specialists in endocrinology and infertility to be aware of juvenile hemochromatosis as a cause of infertility and to evaluate individuals for iron overload prior to correcting the underlying hormonal imbalance [Filali et al 2004].

Therapies Under Investigation

Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.

Mode of Inheritance

Juvenile hemochromatosis is inherited in an autosomal recessive manner.

Risk to Family Members

Parents of a proband

• The parents of an affected individual are obligate heterozygotes (i.e., presumed to be carriers of one HAMP or HJV pathogenic variant based on family history).
• Molecular genetic testing is recommended for the parents of a proband to confirm that each parent is heterozygous for a pathogenic variant in either HAMP or HJV and to allow reliable recurrence risk assessment. (De novo variants are known to occur at a low but appreciable rate in autosomal recessive disorders [Jónsson et al 2017].)
• Heterozygotes (carriers) are not at risk of developing juvenile hemochromatosis. Middle-age-onset hemochromatosis has been reported in some HJV heterozygotes [Kong et al 2019]. However, it is possible that undetected pathogenic variants or rearrangements in HJV or other iron genes are present in these individuals.

Sibs of a proband

• If both parents are known to be heterozygous for a pathogenic variant in either HAMP or HJV, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.
• Heterozygotes (carriers) are not at risk of developing juvenile hemochromatosis. Middle-age-onset hemochromatosis has been reported in some HJV heterozygotes [Kong et al 2019]. However, it is possible that undetected pathogenic variants or rearrangements in HJV or other iron genes are present in these individuals.

Offspring of a proband. Unless an individual with juvenile hemochromatosis has children with an affected individual or a carrier, his/her offspring will be heterozygotes (carriers) for a pathogenic variant in HAMP or HJV.

Other family members. Each sib of the proband's parents is at a 50% risk of being a carrier of a pathogenic variant in HAMP or HJV.

Carrier (Heterozygote) Detection

Carrier testing for at-risk relatives requires prior identification of the HAMP or HJV pathogenic variants in the family.

Related Genetic Counseling Issues

See Management, Evaluation of Relatives at Risk for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.

Family planning

• The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal/preimplantation genetic testing is before pregnancy.
• It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.

Prenatal Testing and Preimplantation Genetic Testing

Once the juvenile hemochromatosis-causing pathogenic variants have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic testing for juvenile hemochromatosis are possible.

Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing. While most centers would consider use of prenatal testing to be a personal decision, discussion of these issues may be helpful.

Molecular Pathogenesis

Diferric transferrin (Tf-Fe2) provides iron to most cells of the body. The control of systemic iron levels occurs through the regulation of:

• Acquisition and delivery according to need
  • Enterocytes. Absorption through duodenal and upper jejunum
  • Macrophages. Senescent erythrocytes
  • Hepatocytes. Tf-Fe2
  • Placental cells. Maternal transferrin
• Recycling. Unidirectional from senescent erythrocytes to the erythroid bone marrow through macrophages
• Storage. Liver and spleen are the main storage organs.

There is no known regulated form of iron excretion; however, 1-2 mg iron are lost daily through cellular exfoliation.

The iron saturation of serum transferrin is both a major indicator and a determinant of systemic iron homeostasis [Anderson & Frazer 2017, Muckenthaler et al 2017]. Cellular iron release occurs through the iron exporter ferroportin, encoded by SLC40A1 (see Differential Diagnosis). Ferroportin activity on cell membranes is predominantly governed post-translationally by hepcidin.

HAMP encodes the liver peptide hepcidin, the master regulator of iron homeostasis. Hepcidin regulates intestinal iron absorption and iron release from storage cells by binding and blocking ferroportin [Aschemeyer et al 2018], thus increased hepcidin expression limits iron absorption via repression of ferroportin while its reduction allows greater iron absorption and macrophage iron release via release of ferroportin.

HJV encodes hemojuvelin (HJV), a main regulator of hepcidin, is a GPI-linked protein that activates hepcidin as a co-receptor for BMP cytokines [Silvestri et al 2019]. Hence, HJV-deficient individuals and mice have undetectable levels of hepcidin, thus explaining the more severe phenotype of individuals with HJV juvenile hemochromatosis. In addition, other hemochromatosis-associated proteins (HFE and transferrin receptor 2 [TFR2]) are iron-dependent positive regulators of HAMP expression [Brissot & Loréal 2016]. Hemochromatosis caused by mutation of HFE, TFR2 (see Differential Diagnosis), as well as HJV involves defective synthesis of hepcidin, and is possibly involved in the same regulatory pathway of hepcidin. Defective HFE or TFR2 prevents the formation of a functional iron sensor and signal transduction effector complex leading to reduced or inadequate hepcidin expression.

Mechanism of disease causation. Autosomal recessive juvenile hemochromatosis occurs through a loss-of-function mechanism.

Literature Cited

• Adams PC, Barton JC. How I treat hemochromatosis. Blood. 2010;116:317–25. [PubMed: 20308595]
• Allen KJ, Bertalli NA, Osborne NJ, Constantine CC, Delatycki MB, Nisselle AE, Nicoll AJ, Gertig DM, McLaren CE, Giles GG, Hopper JL, Anderson GJ, Olynyk JK, Powell LW, Gurrin LC. HealthIron Study Investigators. HFE Cys282Tyr homozygotes with serum ferritin concentrations below 1000 microg/L are at low risk of hemochromatosis. Hepatology. 2010;52:925–33. [PMC free article: PMC2932765] [PubMed: 20583211]
• Anderson GJ, Frazer DM. Current understanding of iron homeostasis. Am J Clin Nutr. 2017;106:1559S–1566S. [PMC free article: PMC5701707] [PubMed: 29070551]
• Angelopoulos NG, Goula AK, Papanikolaou G, Tolis G. Osteoporosis in HFE2 juvenile hemochromatosis. A case report and review of the literature. Osteoporos Int. 2006;17:150–5. [PubMed: 15997423]
• Angelopoulos N, Papanikolaou G, Noutsou M, Rombopoulos G, Goula A, Tolis G. Glucose metabolism, insulin secretion and insulin sensitivity in juvenile hemochromatosis. A case report and review of the literature. Exp Clin Endocrinol Diabetes. 2007;115:192–7. [PubMed: 17427110]
• Aschemeyer S, Qiao B, Stefanova D, Valore EV, Sek AC, Ruwe TA, Vieth KR, Jung G, Casu C, Rivella S, Jormakka M, Mackenzie B, Ganz T, Nemeth E. Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin. Blood. 2018;131:899–910. [PMC free article: PMC5824336] [PubMed: 29237594]
• Backe MB, Moen IW, Ellervik C, Hansen JB, Mandrup-Poulsen T. Iron regulation of pancreatic beta-cell functions and oxidative stress. Annu Rev Nutr. 2016;36:241–73. [PubMed: 27146016]
• Badar S, Busti F, Ferrarini A, Xumerle L, Bozzini P, Capelli P, Pozzi-Mucelli R, Campostrini N, De Matteis G, Marin Vargas S, Giorgetti A, Delledonne M, Olivieri O, Girelli D. Identification of novel mutations in hemochromatosis genes by targeted next generation sequencing in Italian patients with unexplained iron overload. Am J Hematol. 2016;91:420–5. [PubMed: 26799139]
• Bassett ML, Hickman PE, Dahlstrom JE. The changing role of liver biopsy in diagnosis and management of haemochromatosis. Pathology. 2011;43:433–9. [PubMed: 21716156]
• Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, Piga A, Cnaan A. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89:1187–93. [PubMed: 15477202]
• Brissot P, Loréal O. Iron metabolism and related genetic diseases: A cleared land, keeping mysteries. J Hepatol. 2016;64:505–15. [PubMed: 26596411]
• Brissot P, Pietrangelo A, Adams PC, de Graaff B, McLaren CE, Loréal O. Haemochromatosis. Nat Rev Dis Primers. 2018;4:18016. [PMC free article: PMC7775623] [PubMed: 29620054]
• Caines AE, Kpodonu J, Massad MG, Chaer R, Evans A, Lee JC, Geha AS. Cardiac transplantation in patients with iron overload cardiomyopathy. J Heart Lung Transplant. 2005;24:486–8. [PubMed: 15797753]
• Camaschella C, Poggiali E. Towards explaining "unexplained hyperferritinemia". Haematologica. 2009;94:307–9. [PMC free article: PMC2649347] [PubMed: 19252171]
• Castiella A, Alústiza JM, Emparanza JI, Zapata EM, Costero B, Díez MI. Liver iron concentration quantification by MRI: are recommended protocols accurate enough for clinical practice? Eur Radiol. 2011;21:137–41. [PubMed: 20694471]
• Dar FS, Faraj W, Zaman MB, Bartlett A, Bomford A, O'Sullivan A, O'Grady J, Heneghan M, Rela M, Heaton ND. Outcome of liver transplantation in hereditary hemochromatosis. Transpl Int. 2009;22:717–24. [PubMed: 19490544]
• De Gobbi M, Pasquero P, Brunello F, Paccotti P, Mazza U, Camaschella C. Juvenile hemochromatosis associated with B-thalassemia treated by phlebotomy and recombinant human erythropoietin. Haematologica. 2000;85:865–7. [PubMed: 10942934]
• De Gobbi M, Roetto A, Piperno A, Mariani R, Alberti F, Papanikolaou G, Politou M, Lockitch G, Girelli D, Fargion S, Cox TM, Gasparini P, Cazzola M, Camaschella C. Natural history of juvenile haemochromatosis. Br J Haematol. 2002;117:973–9. [PubMed: 12060140]
• Delatycki MB, Allen KJ, Gow P, MacFarlane J, Radomski C, Thompson J, Hayden MR, Goldberg YP, Samuels ME. A homozygous HAMP mutation in a multiply consanguineous family with pseudo-dominant juvenile hemochromatosis. Clin Genet. 2004;65:378–83. [PubMed: 15099344]
• Dhillon BK, Chopra G, Jamwal M, Chandak GR, Duseja A, Malhotra P, Chawla YK, Garewal G, Das R. Adult onset hereditary hemochromatosis is associated with a novel recurrent Hemojuvelin (HJV) gene mutation in north Indians. Blood Cells Mol Dis. 2018;73:14–21. [PubMed: 30195625]
• European Association for the Study of the Liver-European Organisation for Research and Treatment of Cancer. Clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43. [PubMed: 22424438]
• Falize L, Guillygomarc'h A, Perrin M, Laine F, Guyader D, Brissot P, Turlin B, Deugnier Y. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology. 2006;44:472–7. [PubMed: 16871557]
• Faria R, Silva B, Silva C, Loureiro P, Queiroz A, Fraga S, Esteves J, Mendes D, Fleming R, Vieira L, Gonçalves J, Faustino P. Next-generation sequencing of hereditary hemochromatosis-related genes: Novel likely pathogenic variants found in the Portuguese population. Blood Cells Mol Dis. 2016;61:10–5. [PubMed: 27667161]
• Filali M, Le Jeunne C, Durand E, Grinda JM, Roetto A, Daraio F, Bruneval P, Jeunemaitre X, Gimenez-Roqueplo AP. Juvenile hemochromatosis HJV-related revealed by cardiogenic shock. Blood Cells Mol Dis. 2004;33:120–4. [PubMed: 15315789]
• Fu F, Li X, Chen C, Bai Y, Liu Q, Shi D, Sang J, Wang K, Wang M. Non-invasive assessment of hepatic fibrosis: comparison of MR elastography to transient elastography and intravoxel incoherent motion diffusion-weighted MRI. Abdom Radiol (NY). 2020;45:73–82. [PubMed: 31372777]
• Fung EB, Fischer R, Pakbaz Z, Fagaly RL, Vichinsky E, Starr TN, Ewing T, Paulson DN, Hassenzahl WV, Harmatz P. The new SQUID biosusceptometer at Oakland: first year of experience. Neurol Clin Neurophysiol. 2004;2004:5. [PubMed: 16012600]
• Galimberti S, Trombini P, Bernasconi DP, Redaelli I, Pelucchi S, Bovo G, Di Gennaro F, Zucchini N, Paruccini N, Piperno A. Simultaneous liver iron and fat measures by magnetic resonance imaging in patients with hyperferritinemia. Scand J Gastroenterol. 2015;50:429–38. [PubMed: 25633726]
• Gandon Y, Olivie D, Guyader D, Aube C, Oberti F, Sebille V, Deugnier Y. Non-invasive assessment of hepatic iron stores by MRI. Lancet. 2004;363:357–62. [PubMed: 15070565]
• Gordeuk VR, Caleffi A, Corradini E, Ferrara F, Jones RA, Castro O, Onyekwere O, Kittles R, Pignatti E, Montosi G, Garuti C, Gangaidzo IT, Gomo ZA, Moyo VM, Rouault TA, MacPhail P, Pietrangelo A. Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene. Blood Cells Mol Dis. 2003;31:299–304. [PubMed: 14636642]
• Guggenbuhl P, Brissot P, Loréal O. Miscellaneous non-inflammatory musculoskeletal conditions. Haemochromatosis: the bone and the joint. Best Pract Res Clin Rheumatol. 2011;25:649–64. [PubMed: 22142745]
• Hamdi-Rozé H, Ben Ali Z, Ropert M, Detivaud L, Aggoune S, Simon D, Pelletier G, Deugnier Y, David V, Bardou-Jacquet E. Variable expressivity of HJV related hemochromatosis: "juvenile" hemochromatosis? Blood Cells Mol Dis. 2019;74:30–33. [PubMed: 30389309]
• Hattori A, Tomosugi N, Tatsumi Y, Suzuki A, Hayashi K, Katano Y, Inagaki Y, Ishikawa T, Hayashi H, Goto H, Wakusawa S. Identification of a novel mutation in the HAMP gene that causes non-detectable hepcidin molecules in a Japanese male patient with juvenile hemochromatosis. Blood Cells Mol Dis. 2012;48:179–82. [PubMed: 22297252]
• Henninger B, Alustiza J, Garbowski M, Gandon Y. Practical guide to quantification of hepatic iron with MRI. Eur Radiol. 2020;30:383–93. [PMC free article: PMC6890593] [PubMed: 31392478]
• Ikuta K, Hatayama M, Addo L, Toki Y, Sasaki K, Tatsumi Y, Hattori A, Kato A, Kato K, Hayashi H, Suzuki T, Kobune M, Tsutsui M, Gotoh A, Aota Y, Matsuura M, Hamada Y, Tokuda T, Komatsu N, Kohgo Y. Iron overload patients with unknown etiology from national survey in Japan. Int J Hematol. 2017;105:353–60. [PubMed: 27848180]
• Iolascon A, De Falco L. Mutations in the gene encoding DMT1: clinical presentation and treatment. Semin Hematol. 2009;46:358–70. [PubMed: 19786204]
• Island ML, Jouanolle AM, Mosser A, Deugnier Y, David V, Brissot P, Loréal O. A new mutation in the hepcidin promoter impairs its BMP response and contributes to a severe phenotype in HFE related hemochromatosis. Haematologica. 2009;94:720–4. [PMC free article: PMC2675685] [PubMed: 19286879]
• Jacolot S, Le Gac G, Scotet V, Quere I, Mura C, Ferec C. HAMP as a modifier gene that increases the phenotypic expression of the HFE pC282Y homozygous genotype. Blood. 2004;103:2835–40. [PubMed: 14670915]
• Jónsson H, Sulem P, Kehr B, Kristmundsdottir S, Zink F, Hjartarson E, Hardarson MT, Hjorleifsson KE, Eggertsson HP, Gudjonsson SA, Ward LD, Arnadottir GA, Helgason EA, Helgason H, Gylfason A, Jonasdottir A, Jonasdottir A, Rafnar T, Frigge M, Stacey SN, Th Magnusson O, Thorsteinsdottir U, Masson G, Kong A, Halldorsson BV, Helgason A, Gudbjartsson DF, Stefansson K. Parental influence on human germline de novo mutations in 1,548 trios from Iceland. Nature. 2017;549:519–22. [PubMed: 28959963]
• Kirk P, He T, Anderson LJ, Roughton M, Tanner MA, Lam WW, Au WY, Chu WC, Chan G, Galanello R, Matta G, Fogel M, Cohen AR, Tan RS, Chen K, Ng I, Lai A, Fucharoen S, Laothamata J, Chuncharunee S, Jongjirasiri S, Firmin DN, Smith GC, Pennell DJ. International reproducibility of single breathhold T2* MR for cardiac and liver iron assessment among five thalassemia centers. J Magn Reson Imaging. 2010;32:315–9. [PMC free article: PMC2946327] [PubMed: 20677256]
• Kong X, Xie L, Zhu H, Song L, Xing X, Yang W, Chen X. Genotypic and phenotypic spectra of hemojuvelin mutations in primary hemochromatosis patients: a systematic review. Orphanet J Rare Dis. 2019;14:171. [PMC free article: PMC6615163] [PubMed: 31286966]
• Koyama C, Hayashi H, Wakusawa S, Ueno T, Yano M, Katano Y, Goto H, Kidokoro R. Three patients with middle-age-onset hemochromatosis caused by novel mutations in the hemojuvelin gene. J Hepatol. 2005;43:740–2. [PubMed: 16099526]
• Lanktree MB, Sadikovic B, Waye JS, Levstik A, Lanktree BB, Yudin J, Crowther MA, Pare G, Adams PC. Clinical evaluation of a hemochromatosis next-generation sequencing gene panel. Eur J Haematol. 2017;98:228–34. [PubMed: 27753142]
• Lanzara C, Roetto A, Daraio F, Rivard S, Ficarella R, Simard H, Cox TM, Cazzola M, Piperno A, Gimenez-Roqueplo AP, Grammatico P, Volinia S, Gasparini P, Camaschella C. Spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosis. Blood. 2004;103:4317–21. [PubMed: 14982873]
• Lee PL, Barton JC, Brandhagen D, Beutler E. Hemojuvelin (HJV) mutations in persons of European, African-American and Asian ancestry with adult onset haemochromatosis. Br J Haematol. 2004;127:224–9. [PubMed: 15461631]
• Le Gac G, Mons F, Jacolot S, Scotet V, Ferec C, Frebourg T. Early onset hereditary hemochromatosis resulting from a novel TFR2 gene nonsense mutation (R105X) in two siblings of north French descent. Br J Haematol. 2004;125:674–8. [PubMed: 15147384]
• Lok CY, Merryweather-Clarke AT, Viprakasit V, Chinthammitr Y, Srichairatanakool S, Limwongse C, Oleesky D, Robins AJ, Hudson J, Wai P, Premawardhena A, de Silva HJ, Dassanayake A, McKeown C, Jackson M, Gama R, Khan N, Newman W, Banait G, Chilton A, Wilson-Morkeh I, Weatherall DJ, Robson KJ. Iron overload in the Asian community. Blood. 2009;114:20–5. [PubMed: 19342478]
• Lv T, Zhang W, Xu A, Li Y, Zhou D, Zhang B, Li X, Zhao X, Wang Y, Wang X, Duan W, Wang Q, Xu H, Zheng J, Zhao R, Zhu L, Dong Y, Lu L, Chen Y, Long J, Zheng S, Wang W, You H, Jia J, Ou X, Huang J. Non-HFE mutations in haemochromatosis in China: combination of heterozygous mutations involving HJV signal peptide variants. J Med Genet. 2018;55:650–60. [PubMed: 30166352]
• Lynch SR, Skikne BS, Cook JD. Food iron absorption in idiopathic hemochromatosis. Blood. 1989;74:2187–93. [PubMed: 2804357]
• Maeda T, Nakamaki T, Saito B, Nakashima H, Ariizumi H, Yanagisawa K, Hattori A, Tatsumi Y, Hayashi H, Suzuki K, Tomoyasu S. Hemojuvelin hemochromatosis receiving iron chelation therapy with deferasirox: improvement of liver disease activity, cardiac and hematological function. Eur J Haematol. 2011;87:467–9. [PubMed: 21848699]
• Majore S, Binni F, Pennese A, De Santis A, Crisi A, Grammatico P. HAMP gene mutation c.208T>C (p.C70R) identified in an Italian patient with severe hereditary hemochromatosis. Hum Mutat. 2004;23:400. [PubMed: 15024747]
• Masera N, Cattoni A, Decimi V, D'Apolito V, Arosio C, Mariani R, Piperno A. Efficacy of deferasirox for the treatment of iron overload in a child affected by juvenile hemochromatosis. Case Rep Clin Med. 2013;2:126–8.
• Matthes T, Aguilar-Martinez P, Pizzi-Bosman L, Darbellay R, Rubbia-Brandt L, Giostra E, Michel M, Ganz T, Beris P. Severe hemochromatosis in a Portuguese family associated with a new mutation in the 5'UTR of the hepcidin gene. Blood. 2004;104:2181–3. [PubMed: 15198949]
• McNamara L, Gordeuk VR, MacPhail AP. Ferroportin (Q248H) mutations in African families with dietary iron overload. J Gastroenterol Hepatol. 2005;20:1855–8. [PubMed: 16336444]
• Merryweather-Clarke AT, Cadet E, Bomford A, Capron D, Viprakasit V, Miller A, McHugh PJ, Chapman RW, Pointon JJ, Wimhurst VL, Livesey KJ, Tanphaichitr V, Rochette J, Robson KJ. Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. Hum Mol Genet. 2003;12:2241–7. [PubMed: 12915468]
• Milman N, Byg K-E, Ovesen L, Kirchhoff M, Jurgensen K S-L. Iron status in Danish men 1984–94: a cohort comparison of changes in iron stores and the prevalence of iron deficiency and iron overload. Eur J Haematol. 2002;68:332–40. [PubMed: 12225390]
• Milman N, Byg KE, Ovesen L, Kirchhoff M, Jürgensen KS. Iron status in Danish women 1984–1994: a cohort comparison of changes in iron stores and the prevalence of iron deficiency and iron overload. Eur J Haematol. 2003;71:51–61. [PubMed: 12801299]
• Muckenthaler MU, Rivella S, Hentze MW, Galy B. A red carpet for iron metabolism. Cell. 2017;168:344–61. [PMC free article: PMC5706455] [PubMed: 28129536]
• Murphy CJ, Oudit GY. Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment. J Card Fail. 2010;16:888–900. [PubMed: 21055653]
• Pelusi C, Gasparini DI, Bianchi N, Pasquali R. Endocrine dysfunction in hereditary hemochromatosis. J Endocrinol Invest. 2016;39:837–47. [PubMed: 26951056]
• Pietrangelo A, Caleffi A, Henrion J, Ferrara F, Corradini E, Kulaksiz H, Stremmel W, Andreone P, Garuti C. Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes. Gastroenterology. 2005;128:470–9. [PubMed: 15685557]
• Pietrangelo A. Ferroportin disease: pathogenesis, diagnosis and treatment. Haematologica. 2017;102:1972–84. [PMC free article: PMC5709096] [PubMed: 29101207]
• Piperno A, Girelli D, Nemeth E, Trombini P, Bozzini C, Poggiali E, Phung Y, Ganz T, Camaschella C. Blunted hepcidin response to oral iron challenge in HFE-related hemochromatosis. Blood. 2007;110:4096–100. [PubMed: 17724144]
• Piperno A. Molecular diagnosis of hemochromatosis. Expert Opin Med Diagn. 2013;7:161–77. [PubMed: 23530886]
• Porter JB, Walter PB, Neumayr LD, Evans P, Bansal S, Garbowski M, Weyhmiller MG, Harmatz PR, Wood JC, Miller JL, Byrnes C, Weiss G, Seifert M, Grosse R, Grabowski D, Schmidt A, Fischer R, Nielsen P, Niemeyer C, Vichinsky E. Mechanisms of plasma non-transferrin bound iron generation: insights from comparing transfused diamond blackfan anaemia with sickle cell and thalassaemia patients. Br J Haematol. 2014;167:692–6. [PMC free article: PMC4577015] [PubMed: 25209728]
• Porto G, Brissot P, Swinkels DW, Zoller H, Kamarainen O, Patton S, Alonso I, Morris M, Keeney S. EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochromatosis (HH). Eur J Hum Genet. 2016;24:479–95. [PMC free article: PMC4929861] [PubMed: 26153218]
• Ramzan K, Imtiaz F, Al-Ashgar HI, AlSayed M, Sulaiman RA. Juvenile hemochromatosis and hepatocellular carcinoma in a patient with a novel mutation in the HJV gene. Eur J Med Genet. 2017;60:308–11. [PubMed: 28363629]
• Ravasi G, Rausa M, Pelucchi S, Arosio C, Greni F, Mariani R, Pelloni I, Silvestri L, Pineda P, Camaschella C, Piperno A. Transferrin receptor 2 mutations in patients with juvenile hemochromatosis phenotype. Am J Hematol. 2015;90:E226–7. [PubMed: 26408288]
• Ravasi G, Pelucchi S, Mariani R, Silvestri L, Camaschella C, Piperno A. A severe hemojuvelin mutation leading to late onset of HFE2-hemochromatosis. Dig Liver Dis. 2018;50:859–62. [PubMed: 29764732]
• Roetto A, Papanikolaou G, Politou M, Alberti F, Girelli D, Christakis J, Loukopoulos D, Camaschella C. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet. 2003;33:21–2. [PubMed: 12469120]
• Roetto A, Daraio F, Porporato P, Caruso R, Cox TM, Cazzola M, Gasparini P, Piperno A, Camaschella C. Screening hepcidin for mutations in juvenile hemochromatosis: identification of a new mutation (C70R). Blood. 2004;103:2407–9. [PubMed: 14630809]
• Rombout-Sestrienkova E, van Kraaij MG, Koek GH. How we manage patients with hereditary haemochromatosis. Br J Haematol. 2016;175:759–70. [PubMed: 27723100]
• Sahinbegovic E, Dallos T, Aigner E, Axmann R, Manger B, Englbrecht M, Schöniger-Hekele M, Karonitsch T, Stamm T, Farkas M, Karger T, Stölzel U, Keysser G, Datz C, Schett G, Zwerina J. Musculoskeletal disease burden of hereditary hemochromatosis. Arthritis Rheum. 2010;62:3792–8. [PubMed: 20722017]
• Santos PC, Cançado RD, Pereira AC, Schettert IT, Soares RA, Pagliusi RA, Hirata RD, Hirata MH, Teixeira AC, Figueiredo MS, Chiattone CS, Krieger JE, Guerra-Shinohara EM. Hereditary hemochromatosis: mutations in genes involved in iron homeostasis in Brazilian patients. Blood Cells Mol Dis. 2011;46:302–7. [PubMed: 21411349]
• Shizukuda Y, Rosing DR. Iron overload and arrhythmias: Influence of confounding factors. J Arrhythm. 2019;35:575–83. [PMC free article: PMC6686354] [PubMed: 31410226]
• Silvestri L, Nai A, Dulja A, Pagani A. Hepcidin and the BMP-SMAD pathway: An unexpected liaison. Vitam Horm. 2019;110:71–99. [PubMed: 30798817]
• Stenson PD, Mort M, Ball EV, Evans K, Hayden M, Heywood S, Hussain M, Phillips AD, Cooper DN. The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. Hum Genet. 2017;136:665–77. [PMC free article: PMC5429360] [PubMed: 28349240]
• Vaiopoulos G, Papanikolaou G, Politou M, Jibreel I, Sakellaropoulos N, Loukopoulos D. Arthropathy in juvenile hemochromatosis. Arthritis Rheum. 2003;48:227–30. [PubMed: 12528123]
• Varkonyi J, Kaltwasser JP, Seidl C, Kollai G, Andrikovics H, Tordai A. A case of non-HFE juvenile haemochromatosis presenting with adrenocortical insufficiency. Br J Haematol. 2000;109:252–3. [PubMed: 10896410]
• Viveiros A, Schaefer B, Tilg H, Zoller H. Iron matryoshka-haemochromatosis nested in ferroportin disease? Liver Int. 2019;39:1014–5. [PubMed: 31127686]
• Wallace DF, Subramaniam VN. The global prevalence of HFE and non-HFE hemochromatosis estimated from analysis of next-generation sequencing data. Genet Med. 2016;18:618–26. [PubMed: 26633544]

Author Notes

Xenon Pharmaceuticals Inc
Web: www.xenon-pharma.com

International BioIron Society (IBIS)
Two Woodfield Lake
1100 E Woodfield Road
Suite 350
Schaumburg, IL 60173
Phone: 847-517-7225
Text: 847-517-7229
Email: gro.norioib@ofni
Web: bioiron.org

Author History

Angela Bentivegna, PhD (2020-present)
Francesca Bertola, PhD (2020-present)
Y Paul Goldberg, MB ChB, PhD, FRCPC; Xenon Pharmaceuticals Inc (2005-2020)
Julie MacFarlane, MS, CCGC; Xenon Pharmaceuticals Inc (2005-2011)
George Papanikalaou, MD, PhD; National and Kapodistrian University of Athens (2005-2011)
Alberto Piperno, MD (2020-present)

Revision History

• 9 January 2020 (sw) Comprehensive update posted live
• 11 August 2011 (me) Comprehensive update posted live
• 17 February 2005 (me) Review posted live
• 12 July 2004 (pg) Original submission